

# **The novel cardiokine GDF3 predicts adverse fibrotic remodeling post-myocardial infarction**

Nihar Masurkar <sup>a†</sup> PhD, Marion Bouvet <sup>a†</sup> PhD, Damien Logeart <sup>b</sup> MD PhD, Olivier Claude <sup>a</sup> PhD, Maguelonne Roux <sup>c</sup> PhD, Clément Delacroix <sup>a</sup> PhD, Damien Bergerot <sup>d</sup> Msc, Jean-Jacques Mercadier <sup>e</sup> MD PhD, Marc Sirof <sup>b</sup> MD PhD, Barnabas Gellen MD PhD <sup>f</sup>, Marine Livrozet <sup>d</sup> MD PhD, Antoine Fayol <sup>d</sup> MD, Estelle Robidel <sup>a</sup> MsC, David-Alexandre Trégouët <sup>g</sup> PhD, Giovanna Marazzi <sup>a</sup> MD PhD, David Sassoon <sup>a</sup> PhD, Mariana Valente <sup>a</sup> PhD, and Jean-Sébastien Hulot <sup>a,d\*</sup> MD PhD.

## **SUPPLEMENTAL MATERIAL**


**Supplemental Tables : 1**

**Supplemental Figures : 5**


**Supplemental Table 1. PCR primers**

GENE	FORWARD PRIMER (5' TO 3')	REVERSE PRIMER (5' TO 3')
<b><i>CCL8</i></b>	TCTACGCAGTGCTTCTTTGCC	AAGGGGGATCTTCAGCTTTAGTA
<b><i>PRTN3</i></b>	ATGGCTGGAAGCTACCCATC	TGCCACCTACAATCTTGGAG
<b>F10</b>	AGGACTCGGAGGGCAAACCT	TCACGGACCTCTTCATAAGAACA
<b>SAA3</b>	TGCCATCATTCTTTGCATCTTGA	CCGTGAACTTCTGAACAGCCT
<b>APOC4</b>	TGTTCTTGGTCAGCTTTGTAGC	AGGCTGTGGGTCTTGTTTAGG
<b>APOC2</b>	ATGGGGTCTCGGTTCTTCCT	GTCTTCTGGTACAGGTCTTTGG
<b>PROK2</b>	TTGCGACAAGGACTCTCAGT	CCCATAGGTCAGATCCT
<b>CIQTNF3</b>	GCTGGTAAACATAGGTGGCG	GCGGTTCTTCATCAGCTTCA
<b>CELA1</b>	GGGGCTCCTCTGTGAAGAAT	AGCATACTGACCGTTCACCA
<b>GDF3</b>	TTCAGCTTCTCCAGACCAG	CCTTTTCTTTGATGGCAGACAAG
<b>DMKN</b>	CGGGAGTCACACCTTCATCT	AACTTCAGCCACTTCAGCAG
<b>NDP</b>	AGTCTGAGAAGAAGGAGCCC	GCTTCTTTCACTTGCAACCG
<b>RPL13</b>	GGGTGGCCAGCTTAAGTTCT	GAGGAGGCGAAACAAGTCCA


**Online Figure 1. Expression of candidates that were not increased in the ischemic heart.** qPCR evaluation of *REG3G*, *F9*, *CFD*, *17007RIK*, *TRH*, *GM26947*, *ADIPOQ*, *PNOG*, *LIPC*, *MUC6*, *MZB1*, and *AMB P* expression in the infarcted area of MI hearts and the corresponding area of sham hearts (N = 3). Statistical significance was determined by Mann-Whitney test, \*P < 0.05, \*\*P < 0.01 and \*\*\*P < 0.001.




**Online Figure 2. Expression of GDF3 in human hearts.** Representative Western blots and quantification of mature GDF3 in non-failing (NF) (n = 6) and failing hearts (HF) (n = 9) of patients. \*P < 0.05 as determined by Mann Whitney test



**Online Figure 3. Distribution of plasma GDF3 levels.** GDF3 was measured by ELISA in human plasmas collected at day 4±2 post-PCI.




**Online Figure 4. Left ventricular end-diastolic volume indexed for body surface area measured on cardiac MRI 6 months after MI, according to GDF3 quartiles. GDF3 was measured by ELISA in human plasmas collected at day 4±2 post-PCI and patients were classified into 4 quartiles according to GDF3 levels. Statistical significance was determined by one way ANOVA followed by comparison tests, \*P < 0.05**



	GDF3 levels (pg/mL)			
	Quartile 1 [150-807]	Quartile 2 [825-1040]	Quartile 3 [1050-1510]	Quartile 4 [1550-2570]
<b>LVEDVi (ml/m<sup>2</sup>) Mean</b>	91.0	89.1	88.3	105.9
<b>SD</b>	18.2	25.9	16.3	20.9

**Online Figure 5. Left ventricular ejection fraction measured on cardiac MRI 6 months after MI, according to GDF3 quartiles.** GDF3 was measured by ELISA in human plasmas collected at day 4±2 post-PCI and patients were classified into 4 quartiles according to GDF3 levels. Statistical significance was determined by one way ANOVA followed by comparison tests, \*P < 0.05



	GDF3 levels (pg/mL)			
	Quartile 1 [150-807]	Quartile 2 [825-1040]	Quartile 3 [1050-1510]	Quartile 4 [1550-2570]
<b>LVEF (%)</b>				
<b>Mean</b>	52.4	50.5	50.6	44.7
<b>SD</b>	10.7	10.1	8.3	7.2